Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Por Arnulf, Bertrand, Pylypenko, Halyna, Grosicki, Sebastian, Karamanesht, Ievgenii, Leleu, Xavier, van de Velde, Helgi, Feng, Huaibao, Cakana, Andrew, Deraedt, William, Moreau, Philippe
Publicado em 2012

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

Por Moreau, Philippe, Pylypenko, Halyna, Grosicki, Sebastian, Karamanesht, Ievgenii, Leleu, Xavier, Rekhtman, Grigoriy, Masliak, Zvenyslava, Robak, Pawel, Esseltine, Dixie-Lee, Feng, Huaibao, Deraedt, William, van de Velde, Helgi, Arnulf, Bertrand
Publicado no Haematologica (2015)